Smith Cynthia
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
AGIO Valuation Concerns Ahead of Q3 2026 Call. AGIO’s November earnings call sparked debate that the shares might be undervalued by about 28%, while analysts noted the stock appears fully priced against current sales. The company will host its third‑quarter 2026 results call on Nov. 5, which could clarify expectations. After a 29% decline over three months, Truist Securities lowered its target price to $37, reflecting a more cautious view.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
AKBA sees no direct news updates this week. In the past week, there were no company‑specific announcements for Akebia Therapeutics (AKBA). The only notable filing was SCYNEXIS appointing Dr. Steven K. Burke to its board, which does not involve AKBA. As a result, there is little new information to affect AKBA’s market perception at this time.
Transaction History
| SPRO | ▲ Buy | Grant | 10,000 | $0 | 6/23/2026 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 2,816 | $0 | 6/18/2026 | View on chart |
| AKBA | ▲ Buy | Grant | 35,700 | $0 | 6/17/2026 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 2,302 | $0 | 8/11/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 2,120 | $0 | 6/20/2025 | View on chart |
| SPRO | ▲ Buy | Grant | 20,000 | $0 | 6/12/2025 | View on chart |
| AKBA | ▲ Buy | Grant | 35,700 | $0 | 6/10/2025 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 2,302 | $0 | 8/11/2024 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 3,388 | $0 | 6/13/2024 | View on chart |
| AKBA | ▲ Buy | Grant | 30,000 | $0 | 6/6/2024 | View on chart |
| SPRO | ▲ Buy | Grant | 20,000 | $0 | 5/29/2024 | View on chart |
| SPRO | ▲ Buy | Grant | 20,000 | $0 | 10/5/2023 | View on chart |
| AGIO | ▲ Buy | Option Exercise | 2,302 | $0 | 8/11/2023 | View on chart |
| AKBA | ▲ Buy | Grant | 30,000 | $0 | 6/6/2023 | View on chart |
| SPRO | ▲ Buy | Grant | 15,000 | $0 | 9/15/2022 | View on chart |
| AKBA | ▲ Buy | Grant | 13,700 | $0 | 6/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
SPRO among stocks that gapped in Tuesday's session
Spero Therapeutics was listed as a gapping stock on Tuesday, meaning its price opened significantly different from the previous close. Such gaps often reflect a quick shift in market sentiment. The move occurs while the stock is near its $1.19 support level and has a neutral RSI around 49.
SPRO among stocks that gapped in Tuesday's session. Spero Therapeutics was listed as a gapping stock on Tuesday, meaning its price opened significantly different from the previous close. Such gaps often reflect a quick shift in market sentiment. The move occurs while the stock is near its $1.19 support level and has a neutral RSI around 49.